BEIGF
Price
$15.95
Change
-$3.06 (-16.10%)
Updated
Apr 9 closing price
Capitalization
29.46B
XLO
Price
$0.70
Change
+$0.02 (+2.94%)
Updated
Jun 6 closing price
Capitalization
36.25M
60 days until earnings call
Interact to see
Advertisement

BEIGF vs XLO

Header iconBEIGF vs XLO Comparison
Open Charts BEIGF vs XLOBanner chart's image
BeiGene
Price$15.95
Change-$3.06 (-16.10%)
Volume$100
Capitalization29.46B
Xilio Therapeutics
Price$0.70
Change+$0.02 (+2.94%)
Volume$891.06K
Capitalization36.25M
BEIGF vs XLO Comparison Chart
Loading...
XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEIGF vs. XLO commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEIGF is a Hold and XLO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (BEIGF: $15.95 vs. XLO: $0.70)
Brand notoriety: BEIGF and XLO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEIGF: 69% vs. XLO: 57%
Market capitalization -- BEIGF: $29.46B vs. XLO: $36.25M
BEIGF [@Biotechnology] is valued at $29.46B. XLO’s [@Biotechnology] market capitalization is $36.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEIGF’s FA Score shows that 0 FA rating(s) are green whileXLO’s FA Score has 0 green FA rating(s).

  • BEIGF’s FA Score: 0 green, 5 red.
  • XLO’s FA Score: 0 green, 5 red.
According to our system of comparison, BEIGF is a better buy in the long-term than XLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XLO’s TA Score shows that 4 TA indicator(s) are bullish.

  • XLO’s TA Score: 4 bullish, 6 bearish.

Price Growth

BEIGF (@Biotechnology) experienced а 0.00% price change this week, while XLO (@Biotechnology) price change was -34.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

XLO is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEIGF($29.5B) has a higher market cap than XLO($36.2M). BEIGF YTD gains are higher at: 13.766 vs. XLO (-26.702). XLO has higher annual earnings (EBITDA): -58M vs. BEIGF (-116.48M). BEIGF has more cash in the bank: 2.52B vs. XLO (55.3M). XLO has less debt than BEIGF: XLO (8.14M) vs BEIGF (997M). BEIGF has higher revenues than XLO: BEIGF (4.18B) vs XLO (6.34M).
BEIGFXLOBEIGF / XLO
Capitalization29.5B36.2M81,492%
EBITDA-116.48M-58M201%
Gain YTD13.766-26.702-52%
P/E RatioN/AN/A-
Revenue4.18B6.34M65,826%
Total Cash2.52B55.3M4,550%
Total Debt997M8.14M12,245%
TECHNICAL ANALYSIS
Technical Analysis
XLO
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
FOREX / NAMEPrice $Chg $Chg %
RUBCHF0.010.00
+2.75%
Russia Ruble - Switzerland Franc
ECMGX22.17N/A
N/A
Eaton Vance Tx-Mgd Small-Cap C
BRWRX23.81N/A
N/A
MFS Blended Research Growth Eq R1
EURCHF0.94N/A
N/A
Euro - Switzerland Franc
HKDNZD0.21N/A
N/A
Hong Kong Dollar - New Zealand Dollar

BEIGF and

Correlation & Price change

A.I.dvisor tells us that BEIGF and GOVX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BEIGF and GOVX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEIGF
1D Price
Change %
BEIGF100%
N/A
GOVX - BEIGF
29%
Poorly correlated
+2.75%
CING - BEIGF
29%
Poorly correlated
+2.71%
POLBF - BEIGF
25%
Poorly correlated
N/A
XLO - BEIGF
9%
Poorly correlated
+3.20%
CGTX - BEIGF
9%
Poorly correlated
+1.79%
More

XLO and

Correlation & Price change

A.I.dvisor tells us that XLO and CRMD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XLO and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XLO
1D Price
Change %
XLO100%
+3.20%
CRMD - XLO
31%
Poorly correlated
+6.07%
AXON - XLO
31%
Poorly correlated
+1.52%
VKTX - XLO
30%
Poorly correlated
+2.92%
AVTX - XLO
27%
Poorly correlated
-5.31%
AIMD - XLO
26%
Poorly correlated
+1.76%
More